YHB Investment Advisors Inc. Sells 2,556 Shares of Kenvue Inc. (NYSE:KVUE)

YHB Investment Advisors Inc. reduced its stake in Kenvue Inc. (NYSE:KVUE) by 5.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 47,684 shares of the company’s stock after selling 2,556 shares during the period. YHB Investment Advisors Inc.’s holdings in Kenvue were worth $1,143,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in KVUE. LaFleur & Godfrey LLC raised its position in shares of Kenvue by 29.8% in the 4th quarter. LaFleur & Godfrey LLC now owns 81,300 shares of the company’s stock valued at $1,736,000 after buying an additional 18,650 shares in the last quarter. Atria Wealth Solutions Inc. lifted its position in shares of Kenvue by 106.9% during the 4th quarter. Atria Wealth Solutions Inc. now owns 18,257 shares of the company’s stock worth $390,000 after buying an additional 9,432 shares during the last quarter. Private Advisor Group LLC boosted its stake in Kenvue by 34.1% in the fourth quarter. Private Advisor Group LLC now owns 50,076 shares of the company’s stock valued at $1,069,000 after buying an additional 12,729 shares in the last quarter. Ieq Capital LLC grew its position in Kenvue by 20.0% in the fourth quarter. Ieq Capital LLC now owns 12,853 shares of the company’s stock valued at $274,000 after acquiring an additional 2,146 shares during the last quarter. Finally, Sigma Planning Corp grew its position in Kenvue by 2.5% in the fourth quarter. Sigma Planning Corp now owns 39,641 shares of the company’s stock valued at $846,000 after acquiring an additional 955 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on KVUE. Citigroup reissued a “neutral” rating on shares of Kenvue in a report on Friday, June 13th. Barclays increased their price objective on shares of Kenvue from $22.00 to $23.00 and gave the company an “equal weight” rating in a research note on Monday, May 12th. UBS Group boosted their target price on shares of Kenvue from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Friday, May 9th. Canaccord Genuity Group upped their price target on shares of Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. Finally, Redburn Atlantic began coverage on Kenvue in a report on Thursday, April 10th. They set a “neutral” rating and a $23.50 price objective on the stock. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Kenvue currently has a consensus rating of “Hold” and a consensus price target of $25.33.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $21.21 on Wednesday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.60 and a current ratio of 0.86. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $25.17. The firm has a market cap of $40.70 billion, a PE ratio of 38.57, a price-to-earnings-growth ratio of 3.32 and a beta of 0.98. The firm’s fifty day moving average is $22.96 and its 200-day moving average is $22.39.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.01. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. The business had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. During the same period last year, the company earned $0.28 EPS. Kenvue’s revenue for the quarter was down 3.9% compared to the same quarter last year. Sell-side analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th were given a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.87%. Kenvue’s dividend payout ratio (DPR) is 149.09%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.